Volvo Group and Daimler Truck launch Coretura - a Joint Venture to unlock the digital future of commercial vehicles
Following the binding joint venture agreements signed on October 28, 2024, Volvo Group and Daimler Truck have obtained all required regulatory approvals and have now launched the new company Coretura. Following the joint venture transaction, Coretura, based in Gothenburg, Sweden, began operations in the beginning of June 2025.
Karin Rådström, President and CEO of Daimler Truck: "With Coretura, we are setting a clear strategic focus on software development for commercial vehicles. This is a big and really exciting step — not just for us, but for the entire industry and our customers. Together we are starting the digital-driven future of trucks and buses, ultimately making commercial vehicles smarter, more connected, and more efficient than ever before."
Martin Lundstedt, President and CEO of the Volvo Group, adds: "Coretura represents a bold step forward in the evolution of commercial vehicles. By leveraging cutting-edge technology and collaborative innovation, we're setting the stage for a new era of connectivity and efficiency in the industry. This venture underscores our commitment to not only advancing our products but also paving the way for sustainable and intelligent transportation solutions."
Coretura will be led by a four-member Executive Management team consisting of two members from each of the shareholders. Johan Lundén has been appointed as CEO coming from Volvo Group where he previously held responsibility for Strategic Product Planning, Project and Innovation management.
Unlocking the digital future of commercial vehicles
As commercial vehicles are becoming more digital, the mission of Coretura is to build the non-differentiating core, a standardized and open software-defined vehicle platform and dedicated commercial vehicle operating system.
Coretura's activities also include the specification and procurement of centralized high-performance control units dedicated for commercial vehicles and capable of handling large amounts of data. This will decouple software and hardware development cycles, allowing end customers to purchase and update digital applications wirelessly 'over the air,' enhancing safety, efficiency and customer experience.
"This joint venture blends the agility of a start-up with the stability and expertise of our major shareholders. We are proud and energized to lead the digital transformation in the commercial vehicle industry—backed by strong shareholder support and committed to shaping the industry's future." says Johan Lundén, CEO of Coretura.
Starting with around 50 employees, Coretura is set to grow stepwise. This allows the shareholders to pool resources and invest in accordance with technical progress and achievement of milestones. Coretura thereby follows a collaborative co-development approach with its customers, aiming to launch its first products in vehicles by the end of the decade.
Volvo Group and Daimler Truck will remain competitors and continue to differentiate their range of product and services offerings, including their respective digital solutions.
Coretura is open to cooperation and invites new and traditional suppliers and partners who share its values to join in creating the future of the industry.
June 17, 2025
Contact Volvo Group:Claes Eliasson, +46 76 553 7229, press@volvo.com Contact Daimler Truck:Paul Mandaiker, +49 176 30999267, paul.mandaiker@daimlertruck.com
For more information, please visit volvogroup.com For frequent updates, follow us on LinkedIn
The Volvo Group drives prosperity through transport and infrastructure solutions, offering trucks, buses, construction equipment, power solutions for marine and industrial applications, financing and services that increase our customers' uptime and productivity. Founded in 1927, the Volvo Group is committed to shaping the future landscape of sustainable transport and infrastructure solutions. The Volvo Group is headquartered in Gothenburg, Sweden, employs more than 100,000 people and serves customers in almost 190 markets. In 2024, net sales amounted to SEK 527 billion (EUR 46 billion). Volvo shares are listed on Nasdaq Stockholm.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/ab-volvo/r/volvo-group-and-daimler-truck-launch-coretura---a-joint-venture-to-unlock-the-digital-future-of-comm,c4164958
The following files are available for download:
https://mb.cision.com/Main/39/4164958/3507925.pdf
Press release - Volvo Group and Daimler Truck launch Coretura - a Joint Venture to unlock the digital future of commercial vehicles
https://news.cision.com/ab-volvo/i/250617-volvo-group-coretura,c3419375
250617-volvo-group-coretura
View original content:https://www.prnewswire.com/news-releases/volvo-group-and-daimler-truck-launch-coretura---a-joint-venture-to-unlock-the-digital-future-of-commercial-vehicles-302483493.html
SOURCE AB Volvo
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Caterpillar, Komatsu, and Volvo Dominate with Global Reach, Autonomous Tech, and Sustainable Machinery Innovations
Discover the latest insights in the Heavy Construction Equipment Companies Quadrant industry analysis, spotlighting top global players, cutting-edge innovations, and emerging trends. Recognized leaders include industry giants like Caterpillar, Volvo Group, and Komatsu, who are driving advancements in autonomous and sustainable technologies. This market analysis categorizes over 100 companies, with focus on machinery type, application, propulsion, and end-use industry such as mining and construction. Stay informed on the key developments in heavy machinery, crucial for sectors providing raw materials worldwide. Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Heavy Construction Equipment - Company Evaluation Report, 2025" report has been added to Heavy Construction Equipment Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Heavy Construction Equipment. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. The publisher's 360 Quadrants evaluated over 100 companies, of which the Top 12 Heavy Construction Equipment Companies were categorized and recognized as quadrant construction equipment refers to large-scale machinery, typically weighing over 12 metric tons, designed to perform specific tasks in construction, demolition, and mining operations. These machines - whether transportable, semi-permanent, or permanent - are primarily utilized for earthmoving, lifting heavy materials or containers, drilling into soil or rock, and carrying out concreting and paving work. Additionally, heavy construction equipment plays a crucial role in mining and construction activities that supply raw materials to various industrial market is segmented based on several criteria, including machinery type, application, propulsion type, power output, engine capacity, end-use industry, and geographic region. By end-use industry, the market includes sectors such as mining, infrastructure development, building & construction, forestry & agriculture, and other specialized applications. Based on machinery type, the equipment is categorized into excavation & demolition, heavy lifting, material handling, recycling & waste management, transportation, and tunneling machinery - each serving distinct functional requirements across construction and industrial PlayersKey players in the Heavy Construction Equipment market include major global corporations and specialized innovators such as Caterpillar, Volvo Group, Komatsu, Hitachi Construction Machinery Co., Ltd., Terex Corporation, Liebherr Ag, Sany Group, Hd Hyundai, Xcmg Group, Cnh Industrial N.v., Wacker Neuson Se, and Sumitomo Heavy Industries, Ltd. These companies are actively investing in research and development, forming strategic partnerships, and engaging in collaborative initiatives to drive innovation, expand their global footprint, and maintain a competitive edge in this rapidly evolving 3 Companies CaterpillarCaterpillar stands as a leader, recognized for its broad range of heavy machinery, including excavators and loaders. This company excels in enhancing its Company Product Portfolio, emphasizing autonomous and sustainable technology. With a strong presence in over 500 locations worldwide, Caterpillar harnesses a vast dealer network to sustain its Company Positions globally. Its approach to integrating advanced technologies, like autonomous CAT 777 trucks, illustrates its forward-thinking strategy in Company thrives with extensive operations in the Asia-Pacific and American regions. Known for developing innovative machinery, Komatsu enhances its Company Ranking through strategic acquisitions, such as GHH Group GmbH, reflecting its commitment to expanding its Company Product Portfolio. Operating through various segments such as Construction, Mining, and Utility Equipment, Komatsu continues to gain traction by exploring electric and autonomous machine GroupVolvo Group is another pivotal player, renowned for its construction-related products. The company's focus on innovation in electric and hybrid machinery exemplifies its dedication to sustainable development. With a global footprint in multiple regions, Volvo's strategic expansions reflect its robust approach toward improving its Company Positioning. The group's advanced technology ensures efficiency and high performance, reinforcing their stronghold in the heavy construction equipment Topics Covered: 1 Introduction1.1 Market Definition1.2 Stakeholders2 Executive Summary3 Market Overview3.1 Introduction3.2 Market Dynamics3.2.1 Drivers3.2.1.1 Increasing Investments and Developments in Construction and Infrastructure Sectors3.2.1.2 Rapid Urbanization and Population Growth3.2.1.3 Technological Advancements and Upgradation of Equipment3.2.1.4 Government Investments and Supportive Policies for Sustainable Solutions3.2.2 Restraints3.2.2.1 Substantial Capital Investment3.2.2.2 Socio-Economic Effects of Heavy Construction Activities3.2.3 Opportunities3.2.3.1 Demand for Autonomous Heavy Construction Equipment3.2.3.2 Electrification and Digitization of Equipment3.2.3.3 Renting or Leasing Equipment3.2.4 Challenges3.2.4.1 Development of Alternative Optimized Solutions3.2.4.2 Lack of Skilled Labor Force and Maintenance and Repair-Related Issues3.3 Porter's Five Forces Analysis3.3.1 Threat of New Entrants3.3.2 Threat of Substitutes3.3.3 Bargaining Power of Suppliers3.3.4 Bargaining Power of Buyers3.3.5 Intensity of Competitive Rivalry3.4 Supply Chain Analysis3.4.1 Raw Material/Component Analysis3.4.2 Final Product Analysis3.5 Value Chain Analysis3.6 Ecosystem Analysis3.7 Technology Analysis3.7.1 Key Technologies3.7.1.1 Autonomous Heavy Construction Equipment3.7.2 Complementary Technologies3.7.2.1 Connected Technologies3.7.2.2 Grade Control System3.8 Impact of Ai/Gen Ai on Heavy Construction Equipment Market3.8.1 Top Use Cases and Market Potential3.8.2 Best Practices in Heavy Construction Equipment Market3.8.3 Case Studies of Ai Implementation in Heavy Construction Equipment Market3.8.4 Interconnected Adjacent Ecosystem and Impact on Market Players3.8.5 Clients' Readiness to Adopt Generative Ai in Heavy Construction Equipment Market3.9 Patent Analysis3.9.1 Introduction3.9.2 Methodology3.9.3 Document Type3.9.4 Insights3.9.5 Legal Status of Patents3.9.6 Jurisdiction Analysis3.9.7 Top Applicants3.9.8 List of Patents by Volvo Group3.9.9 List of Patents by Doosan Infracore Co., Ltd.3.9.10 List of Patents by Korea Ind Tech Inst.3.10 Key Conferences and Events, 2024-20253.11 Trends and Disruptions Impacting Customer Business4 Competitive Landscape4.1 Overview4.2 Key Player Strategies/Right to Win4.3 Revenue Analysis, 2019-20234.4 Market Share Analysis, 20234.5 Brand/Product Comparison4.5.1 Excavators (Caterpillar)4.5.2 Excavators (Komatsu)4.5.3 Excavators (Xcmg Group)4.5.4 Excavators (Volvo Group)4.6 Company Evaluation Matrix: Key Players, 20234.6.1 Stars4.6.2 Emerging Leaders4.6.3 Pervasive Players4.6.4 Participants4.6.5 Company Footprint: Key Players, 20234.6.5.1 Company Footprint4.6.5.2 Region Footprint4.6.5.3 Machinery Type Footprint4.6.5.4 Application Footprint4.6.5.5 Propulsion Type Footprint4.6.5.6 Power Output Footprint4.6.5.7 Engine Capacity Footprint4.6.5.8 End-Use Industry Footprint4.7 Company Evaluation Matrix: Startups/Smes, 20234.7.1 Progressive Companies4.7.2 Responsive Companies4.7.3 Dynamic Companies4.7.4 Starting Blocks4.7.5 Competitive Benchmarking: Startups/Smes, 20234.7.5.1 Detailed List of Key Startups/Smes4.7.5.2 Competitive Benchmarking of Key Startups/Smes4.8 Company Valuation and Financial Metrics4.9 Competitive Scenario4.9.1 Product Launches4.9.2 Deals5 Company Profiles Caterpillar Volvo Group Komatsu Hitachi Construction Machinery Co., Ltd. Terex Corporation Liebherr Ag Sany Group Hd Hyundai Xcmg Group Cnh Industrial N.V. Wacker Neuson Se Sumitomo Heavy Industries, Ltd. Jc Bamford Excavators Ltd. Manitou Group Escorts Kubota Limited Deere and Company Zoomlion Heavy Industry Science & Technology Co., Ltd. Kobelco Construction Machinery Co., Ltd. Hiab Hidromek Doosan Bobcat Mahindra Construction Equipment For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
11 hours ago
- Wall Street Journal
Swedish Children's Brand Polarn O. Pyret Pulls Out of U.S. Over Tariffs
Since 2009, Swedish brand Polarn O. Pyret has sold kid-size outerwear to a loyal fan base of outdoorsy American parents. Now, citing tariffs, the company is pulling out of the U.S. Jennifer Athanason, owner of the brand's U.S. franchise, said she and the Swedish company decided together to close Polarn O. Pyret USA and halt all U.S. sales by the end of the year. After several years of strong sales fueled by pandemic-era interest in outdoor activities, Athanason said, her company has taken a hit this year from tariffs and a weaker U.S. dollar, making it more costly to purchase inventory from the Swedish parent company.
Yahoo
12 hours ago
- Yahoo
Denmark Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring Novo Nordisk, H. Lundbeck, Leo, Orifarm, ALK-Abell, Xellia, Takeda, Sandoz, Ferring Pharmaceuticals, FUJIFILM
Denmark's pharmaceutical market is projected to grow from US$ 3.81 billion in 2024 to US$ 5.20 billion by 2033, with a CAGR of 3.52%. Key drivers include advanced health data infrastructure, supportive government policies, heavy R&D investment, and contributions from pharmaceutical giants like Novo Nordisk and Lundbeck. The aging population, rise in chronic diseases, and demand for innovative treatments further fuel growth. However, challenges such as regulatory complexity and sustainability pressures persist. The market encompasses a wide range of therapeutic classes and distribution channels, making Denmark a competitive hub for pharmaceutical R&D and innovation. Danish Pharmaceutical Market Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Denmark Pharmaceutical Market - Drug Development & Forecast 2025-2033" report has been added to Pharmaceutical Market is expected to reach US$ 5.20 billion by 2033 from US$ 3.81 billion in 2024, with a CAGR of 3.52% from 2025 to 2033 Heavy R&D spending, government assistance, well-developed healthcare system, aging population, growth in the incidence of chronic diseases, advances in biotechnology, world demand for exports, and the location of world-class pharmaceutical giants such as Novo Nordisk and Lundbeck are all determinants of Denmark's expanding pharmaceutical market. Investigation, research, production, and promotion of drugs and therapies utilized to cure, prevent, or control disease fall within the pharmaceutical sector. Through the provision of innovative medical treatments and increased life expectancy and quality of life, it plays an important role in world medicine. Scientific breakthroughs, government approvals, and the ongoing demand for effective treatments drive this industry. Both small biotech firms and international corporations are prominent players. Prescription drugs, vaccines, and over-the-counter drugs are all pharmaceuticals. The sector often collaborates with research and clinical institutions to accelerate development and is highly regulated to ensure safety and efficacy of R&D expenditures, a collaborative academic and health environment, and supportive government regulations are the primary impetus for Denmark's pharmaceutical industry. Major contributions are made by leading global companies such as Novo Nordisk and Lundbeck through specialty medicine creation and global exports. Demand within the domestic market is also boosted by an aging population and the spread of chronic diseases such as diabetes. Innovation through personalized therapy and real-world evidence creation are enabled by advanced health data infrastructure in Denmark. Its global competitiveness is enhanced by an open regulatory system and access to EU markets. These combine to offer a robust, future-proof pharmaceutical sector with scope to Drivers for the Denmark Pharmaceutical Market Advanced Health Data InfrastructureOne of the key drivers for Denmark's pharmaceutical market's growth is its advanced heath data infrastructure. With biobanks, illness registries, and population-level electronic health records, the country boasts one of the most advanced and unified systems of healthcare data in the world. Since every Danish citizen is assigned a personal identification number, medical records can be exactly correlated between clinics, hospitals, and pharmacies. The approach opens up real-world data to academics and pharma companies to facilitate post-marketing surveillance, drug development, and clinical trials. Such access reduces the cost and time-to-market of research as well as speeds up pharmacovigilance and personalized treatment innovation. It also enhances the quality and efficiency of clinical trials by enabling long-term follow-up and targeted patient recruitment. In addition, Denmark is a safe destination for international collaboration due to the stringent data protection legislation that ensures patient confidentiality. This technological advantage enhances Denmark's competitiveness in the life sciences world and makes it a leading site for pharmaceutical R& Government PoliciesDenmark's pharma industry is growing largely due to the favorable government policies of the country. Denmark has established a comprehensive Life Sciences Growth Plan incorporating 36 initiatives across six key areas such as clinical trials, R&D, and regulatory environments. This strategic plan aims to further consolidate Denmark's reputation as a leading life sciences nation by fostering innovation and streamlining establishment of a "one-stop-shop" for drug companies that simplifies and quickens the regulatory approval process is an essential component of this program. By reducing administrative barriers, this program makes it easier for businesses to set up and expand production sites in Denmark. In addition, Denmark's climate agreement with the pharmaceutical industry illustrates its commitment to environmental responsibility. Consistent with international environmental aims, our partnership works to support green innovation and reduce CO2 emissions. Overall, taken as a package, all these beneficial government programs offer a good environment for pharmaceutical companies to expand, innovate, and become globally competitive for Denmark's pharmaceutical R&D InvestmentHigh investment in research and development (R&D) is one of the factors propelling the growth of the pharmaceutical market in Denmark. With a significant proportion being allocated to life sciences and pharmaceuticals, the country has some of the highest R&D expenditures per GDP of any nation globally. Both the public funding of the Danish government and substantial contributions from the private sector - particularly from major players such as Novo Nordisk and Lundbeck - funding this hospitals, and enterprise are in close collaboration to facilitate Denmark's R&D environment that encourages innovation in biotechnology, personalized medicine, and drug development. Tax reductions, subsidies, and strategic initiatives such as the Life Sciences Growth Plan are some of the government measures that actively encourage R&D. Contemporary research infrastructure and highly skilled staff are also available, which adds to Denmark's competitive edge. This robust R&D climate accelerates the development of novel treatments, attracts foreign partnerships, and makes Denmark a world leader in clinical excellence and pharmaceutical in the Denmark Pharmaceutical Market Regulatory Complexity and EU ComplianceEU compliance and regulatory complexity provide major obstacles for Denmark's pharmaceutical industry. Businesses have to deal with two sets of regulations: strict European Union guidelines and Danish state laws. This results in a complicated and frequently drawn-out approval process for new medications and clinical studies, which can raise expenses and postpone market entry. Startups and small and medium-sized businesses (SMEs) frequently find it difficult to satisfy these standards due to the resource requirements and administrative load. Furthermore, ongoing adaptation is necessary due to the EU's periodic revisions and harmonization initiatives. For Danish pharmaceutical businesses, sustaining innovation speed while balancing compliance is still a major and Green TransitionFor Denmark's pharmaceutical industry, sustainability and the green transition pose increasing obstacles. There is growing pressure on the business to lessen its environmental impact, which includes controlling water use in manufacturing processes, cutting carbon emissions, and limiting waste. Significant investments in cleaner technologies and process innovations are necessary to meet Denmark's aggressive climate targets and EU environmental requirements. Pharmaceutical businesses also need to strike a balance between sustainability measures and preserving cost-effectiveness and production efficiency. Changes in sourcing procedures and supply networks are also necessary for this shift. The Danish pharmaceutical industry must overcome the difficult task of successfully incorporating green practices while maintaining its competitiveness in order to keep up with worldwide sustainability trends. Key Players Analysis: Company Overview, Key Persons, Recent Development & Strategies, SWOT Analysis, Sales Analysis Novo Nordisk A/S H. Lundbeck A/S Leo Pharma A/S Orifarm Group A/S ALK-Abell A/S Xellia ApS Takeda Pharma A/S Sandoz A/S Ferring Pharmaceuticals A/S FUJIFILM Diosynth Biotechnologies Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $3.81 Billion Forecasted Market Value (USD) by 2033 $5.2 Billion Compound Annual Growth Rate 3.5% Regions Covered Denmark Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Denmark Pharmaceutical Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Therapeutic Class6.2 By Drug Type6.3 By Prescription Type6.4 By Distribution Channel7. Therapeutic Class7.1 Cancer7.1.1 Market Analysis7.1.2 Market Size & Forecast7.2 Infectious Diseases7.3 Cardiovascular Diseases7.4 Diabetes7.5 Respiratory Diseases7.6 Central Nervous System Disorders7.7 Autoimmune Diseases7.8 Others8. Drug Type8.1 Branded8.1.1 Market Analysis8.1.2 Market Size & Forecast8.2 Generic9. Prescription Type9.1 OTC Drugs9.1.1 Market Analysis9.1.2 Market Size & Forecast9.2 Prescription Drugs10. Distribution Channel10.1 Hospital Pharmacy10.1.1 Market Analysis10.1.2 Market Size & Forecast10.2 Retail Pharmacy10.3 Others11. Value Chain Analysis12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Competition12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threats14. Pricing Benchmark Analysis14.1 Novo Nordisk A/S14.2 H. Lundbeck A/S14.3 Leo Pharma A/S14.4 Orifarm Group A/S14.5 ALK-Abell A/S14.6 Xellia ApS14.7 Takeda Pharma A/S14.8 Sandoz A/S14.9 Ferring Pharmaceuticals A/S14.10 FUJIFILM Diosynth Biotechnologies15. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Danish Pharmaceutical Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
